Cipla Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Cipla de 13.7% y 10.4% por año respectivamente. Se prevé que el BPA crezca en un 13.7% al año. Se espera que la rentabilidad financiera sea de 13.1% en 3 años.
Información clave
13.7%
Tasa de crecimiento de los beneficios
13.71%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 16.6% |
| Tasa de crecimiento de los ingresos | 10.4% |
| Rentabilidad financiera futura | 13.13% |
| Cobertura de analistas | Good |
| Última actualización | 21 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Artículo de análisis • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Artículo de análisis • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Recent updates
Artículo de análisis • May 16
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
Actualización de narrativa • Apr 27
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Actualización de narrativa • Apr 12
CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).Actualización de narrativa • Mar 27
CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).Actualización de narrativa • Mar 13
CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).Actualización de narrativa • Feb 27
CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).Actualización de narrativa • Feb 13
CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).Actualización de narrativa • Jan 30
CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Artículo de análisis • Jan 28
Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...Artículo de análisis • Jan 17
The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Actualización de narrativa • Jan 16
CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Artículo de análisis • Dec 29
We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Nov 20
Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Nov 02
Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Artículo de análisis • Sep 24
Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Artículo de análisis • Sep 06
Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Actualización de narrativa • Sep 04
Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Artículo de análisis • Jul 13
Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Artículo de análisis • Jun 03
Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Nueva narrativa • Nov 10
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 3/31/2029 | 378,943 | 57,759 | 37,701 | 55,901 | 14 |
| 3/31/2028 | 346,374 | 51,196 | 36,108 | 49,851 | 35 |
| 3/31/2027 | 310,811 | 41,864 | 30,077 | 43,810 | 35 |
| 3/31/2026 | 277,117 | 38,792 | 9,048 | 39,400 | N/A |
| 12/31/2025 | 279,672 | 45,464 | N/A | N/A | N/A |
| 9/30/2025 | 279,658 | 54,411 | 27,544 | 42,949 | N/A |
| 6/30/2025 | 274,796 | 53,925 | N/A | N/A | N/A |
| 3/31/2025 | 272,674 | 52,725 | 34,653 | 50,050 | N/A |
| 12/31/2024 | 267,201 | 49,897 | N/A | N/A | N/A |
| 9/30/2024 | 262,642 | 44,751 | 29,520 | 45,008 | N/A |
| 6/30/2024 | 258,922 | 43,035 | N/A | N/A | N/A |
| 3/31/2024 | 255,367 | 41,216 | 27,846 | 41,339 | N/A |
| 12/31/2023 | 251,163 | 37,082 | N/A | N/A | N/A |
| 9/30/2023 | 243,407 | 34,532 | 25,988 | 37,924 | N/A |
| 6/30/2023 | 235,108 | 31,112 | N/A | N/A | N/A |
| 3/31/2023 | 225,593 | 28,019 | 20,736 | 32,377 | N/A |
| 12/31/2022 | 222,187 | 26,383 | N/A | N/A | N/A |
| 9/30/2022 | 218,874 | 25,660 | 20,120 | 29,160 | N/A |
| 6/30/2022 | 216,105 | 24,884 | N/A | N/A | N/A |
| 3/31/2022 | 217,078 | 25,168 | 26,285 | 33,259 | N/A |
| 12/31/2021 | 210,718 | 25,681 | N/A | N/A | N/A |
| 9/30/2021 | 207,616 | 25,876 | 28,362 | 37,113 | N/A |
| 6/30/2021 | 202,801 | 25,417 | N/A | N/A | N/A |
| 3/31/2021 | 191,205 | 24,049 | 29,418 | 37,552 | N/A |
| 12/31/2020 | 188,779 | 22,374 | N/A | N/A | N/A |
| 9/30/2020 | 180,802 | 18,403 | 23,627 | 31,968 | N/A |
| 6/30/2020 | 174,377 | 16,462 | N/A | N/A | N/A |
| 3/31/2020 | 170,805 | 15,465 | 20,684 | 30,685 | N/A |
| 12/31/2019 | 171,206 | 16,678 | N/A | N/A | N/A |
| 9/30/2019 | 167,572 | 16,489 | N/A | 25,720 | N/A |
| 6/30/2019 | 163,733 | 15,546 | N/A | N/A | N/A |
| 3/31/2019 | 163,232 | 15,277 | N/A | 16,911 | N/A |
| 12/31/2018 | 155,224 | 13,391 | N/A | N/A | N/A |
| 9/30/2018 | 154,287 | 14,074 | N/A | N/A | N/A |
| 6/30/2018 | 154,992 | 14,530 | N/A | N/A | N/A |
| 3/31/2018 | 151,053 | 14,105 | N/A | 14,628 | N/A |
| 12/31/2017 | 147,618 | 11,701 | N/A | N/A | N/A |
| 9/30/2017 | 144,951 | 11,444 | N/A | N/A | N/A |
| 6/30/2017 | 141,637 | 10,762 | N/A | N/A | N/A |
| 3/31/2017 | 143,340 | 10,064 | N/A | 23,818 | N/A |
| 12/31/2016 | 142,509 | 11,213 | N/A | N/A | N/A |
| 9/30/2016 | 137,547 | 10,071 | N/A | N/A | N/A |
| 6/30/2016 | 134,335 | 12,219 | N/A | N/A | N/A |
| 3/31/2016 | 135,480 | 13,600 | N/A | 17,408 | N/A |
| 12/31/2015 | 135,044 | 16,847 | N/A | N/A | N/A |
| 9/30/2015 | 131,633 | 16,694 | N/A | N/A | N/A |
| 6/30/2015 | 124,782 | 15,368 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (13.7% al año) de CIPLA es superior a la tasa de ahorro (6.9%).
Beneficios vs. Mercado: Se prevé que los beneficios (13.7% al año) de CIPLA crezcan menos que el mercado Indian (16.3% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de CIPLA crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (10.4% al año) de CIPLA crezcan más despacio que el mercado de Indian (10.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 10.4% al año) de CIPLA crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de CIPLA sea baja dentro de 3 años (13.1%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 13:42 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cipla Limited está cubierta por 56 analistas. 35 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |